Stock Information
Kyverna Therapeutics Inc (KYTX)
Ticker Symbol: KYTX
Exchange: NASDAQ
Sector: Biotechnology
Market Cap: $501.56 mil
Piotroski score: 2
PE Ratio: N/A
EPS (TTM): -2.94
Revenue (TTM): $0.00 M
Dividend Yield: N/A
ROE: -81.91%
Latest News
-
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials Transcript
Thu, Sep 24, 2026 1:49 PM
-
Kyverna Reports One-Year Miv-Cel Data From SPS and gMG Trials
Thu, Sep 24, 2026 10:39 AM
-
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
Thu, Sep 24, 2026 10:00 AM
-
Kyverna Therapeutics Announces One-year Topline Data From KYSA-8, Its Trial Of Miv-Cel In Patients With Stiff Person Syndrome, And Topline Longer-Term Follow-up Data From Phase 2 Of KYSA-6, Its Trial In Patients With Generalized Myasthenia Gravis; Topline Durability Data Reinforce Potential For Single-dose Miv-Cel To Free Patients From Lifelong Disease Burden And Chronic Immunotherapies, Further Highlighting Miv-Cel’s Differentiated Construct
Thu, Sep 24, 2026 6:05 AM
Key Financials
Financial data not available
